Per Soelberg SÃ¸rensen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3744973/publications.pdf

Version: 2024-02-01

337 papers	34,965 citations	7568 77 h-index	4015 176 g-index
347 all docs	347 docs citations	347 times ranked	27936 citing authors

#	Article	IF	Citations
1	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology, The, 2018, 17, 162-173.	10.2	4,605
2	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 2011, 476, 214-219.	27.8	2,400
3	Defining the clinical course of multiple sclerosis. Neurology, 2014, 83, 278-286.	1.1	2,344
4	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 2013, 45, 1353-1360.	21.4	1,213
5	The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain, 2009, 132, 1175-1189.	7.6	1,182
6	Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet, The, 2001, 357, 1576-1582.	13.7	1,025
7	The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurology, The, 2010, 9, 520-532.	10.2	914
8	A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2010, 362, 416-426.	27.0	791
9	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science, 2019, 365, .	12.6	710
10	Remyelination is extensive in a subset of multiple sclerosis patients. Brain, 2006, 129, 3165-3172.	7.6	667
11	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 96-120.	3.0	458
12	Acute Respiratory Tract Infections and Mannose-Binding Lectin Insufficiency During Early Childhood. JAMA - Journal of the American Medical Association, 2001, 285, 1316.	7.4	381
13	The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review. Multiple Sclerosis Journal, 2015, 21, 305-317.	3.0	381
14	EFNS guidelines on diagnosis and management of neuromyelitis optica. European Journal of Neurology, 2010, 17, 1019-1032.	3.3	376
15	Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet, The, 2003, 362, 1184-1191.	13.7	366
16	Metastatic spinal cord compression. Acta Neurochirurgica, 1990, 107, 37-43.	1.7	347
17	Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet, The, 2000, 355, 2189-2193.	13.7	338
18	Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. Nature Genetics, 2015, 47, 717-726.	21.4	310

#	Article	IF	Citations
19	Widespread Demyelination in the Cerebellar Cortex in Multiple Sclerosis. Brain Pathology, 2007, 17, 38-44.	4.1	301
20	Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet, The, 2000, 355, 2194-2198.	13.7	295
21	A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. Multiple Sclerosis Journal, 2015, 21, 263-281.	3.0	273
22	EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. European Journal of Neurology, 2008, 15, 893-908.	3.3	272
23	Demyelination versus remyelination in progressive multiple sclerosis. Brain, 2010, 133, 2983-2998.	7.6	261
24	Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet, The, 2017, 389, 1347-1356.	13.7	252
25	Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurology, The, 2011, 10, 745-758.	10.2	247
26	Stroke incidence and risk factors for stroke in Copenhagen, Denmark.. Stroke, 1988, 19, 1345-1353.	2.0	235
27	Prognostic factors in metastatic spinal cord compression: a prospective study using multivariate analysis of variables influencing survival and gait function in 153 patients. International Journal of Radiation Oncology Biology Physics, 2000, 46, 1163-1169.	0.8	231
28	Safety and efficacy of cladribine tablets in patients with relapsingâ€“remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Multiple Sclerosis Journal, 2018, 24, 1594-1604.	3.0	227
29	Guidelines on use of antiâ€IFNâ€Î² antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFNâ€Î² antibodies in multiple sclerosis. European Journal of Neurology, 2005, 12, 817-827.	3.3	226
30	Symptoms and signs in metastatic spinal cord compression: a study of progression from first symptom until diagnosis in 153 patients. European Journal of Cancer, 1994, 30, 396-398.	2.8	224
31	Immunogenicity of interferon-? in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration. Annals of Neurology, 2000, 48, 706-712.	5.3	224
32	Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Multiple Sclerosis Journal, 2012, 18, 143-152.	3.0	220
33	Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression. PLoS ONE, 2013, 8, e57820.	2.5	213
34	Metastatic epidural spinal cord compression. Results of treatment and survival. Cancer, 1990, 65, 1502-1508.	4.1	209
35	Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurology, The, 2011, 10, 329-337.	10.2	199
36	Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology, 2005, 65, 33-39.	1.1	190

#	Article	IF	Citations
37	Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurology, The, 2010, 9, 740-750.	10.2	188
38	Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet, The, 2004, 364, 1149-1156.	13.7	181
39	Multiple Sclerosis After Infectious Mononucleosis. Archives of Neurology, 2007, 64, 72.	4.5	170
40	A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. Journal of Neurology, 2014, 261, 773-783.	3.6	168
41	Intracranial pressure and cerebrospinal fluid outflow conductance in healthy subjects. Journal of Neurosurgery, 1991, 74, 597-600.	1.6	162
42	Using Smartphones and Wearable Devices to Monitor Behavioral Changes During COVID-19. Journal of Medical Internet Research, 2020, 22, e19992.	4.3	155
43	FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. Nature Medicine, 2014, 20, 272-282.	30.7	141
44	Cell-based therapeutic strategies for multiple sclerosis. Brain, 2017, 140, 2776-2796.	7.6	139
45	A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 282-293.	3.0	131
46	A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 318-331.	3.0	131
47	Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. Tissue Antigens, 2004, 63, 237-247.	1.0	130
48	Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. Journal of Neurology, 2014, 261, 1170-1177.	3.6	127
49	EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. European Journal of Neurology, 2005, 12, 939-946.	3.3	123
50	Intravenous immunoglobulin G for the treatment of relapsingâ€“remitting multiple sclerosis: a metaâ€analysis. European Journal of Neurology, 2002, 9, 557-563.	3.3	121
51	Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon Î²1a. Annals of Neurology, 2003, 53, 718-724.	5.3	120
52	Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Multiple Sclerosis Journal, 2016, 22, 1386-1396.	3.0	118
53	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. Cell, 2018, 175, 1679-1687.e7.	28.9	115
54	Cerebrospinal fluid flow and production in patients with normal pressure hydrocephalus studied by MRI. Neuroradiology, 1994, 36, 210-215.	2.2	114

#	Article	IF	Citations
55	Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurology, The, 2011, 10, 691-701.	10.2	114
56	Danish very-low-dose aspirin after carotid endarterectomy trial.. Stroke, 1988, 19, 1211-1215.	2.0	112
57	Differential microRNA expression in blood in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1849-1857.	3.0	110
58	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurology, The, 2019, 18, 185-197.	10.2	110
59	Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets) Tj ETQq1 1 0.784314 rgBT /Overloc	3.0	109
60	Giantâ€cell Arteritis, Temporal Arteritis and Polymyalgia Rheumatica. Acta Medica Scandinavica, 1977, 201, 207-213.	0.0	108
61	IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology, 2004, 63, 2028-2033.	1.1	107
62	The Six Spot Step Test: a new measurement for walking ability in multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 495-500.	3.0	104
63	The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Therapeutic Advances in Neurological Disorders, 2016, 9, 44-52.	3.5	103
64	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. Multiple Sclerosis Journal, 2018, 24, 590-603.	3.0	101
65	A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 342-349.	3.0	100
66	Risk Factors for Acute Respiratory Tract Infections in Young Greenlandic Children. American Journal of Epidemiology, 2003, 158, 374-384.	3.4	98
67	NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurology, The, 2009, 8, 519-529.	10.2	95
68	New management algorithms in multiple sclerosis. Current Opinion in Neurology, 2014, 27, 246-259.	3.6	95
69	Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 29, 168-174.	2.0	94
70	Cerebral blood flow in patients with normal-pressure hydrocephalus before and after shunting. Journal of Neurosurgery, 1987, 66, 379-387.	1.6	92
71	Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Multiple Sclerosis Journal, 2013, 19, 1533-1538.	3.0	92
72	Smoking and oral contraceptives as risk factors for cervical carcinomaIn situ. , 1999, 81, 357-365.		91

#	Article	IF	Citations
73	The Multiple Sclerosis Care Unit. Multiple Sclerosis Journal, 2019, 25, 627-636.	3.0	90
74	Comorbidity in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 851.	2.4	89
75	Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 431-436.	3.0	88
76	Motor Disturbances in Normal-Pressure Hydrocephalus. Archives of Neurology, 1986, 43, 34.	4.5	86
77	A Placebo-Controlled, Double-Blind, Cross-Over Trial of Flunarizine in Common Migraine. Cephalalgia, 1986, 6, 7-14.	3.9	84
78	Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. European Journal of Neurology, 2009, 16, 420-423.	3.3	84
79	Initial high-efficacy disease-modifying therapy in multiple sclerosis. Neurology, 2020, 95, e1041-e1051.	1.1	83
80	Sexual dysfunction in male and female patients with epilepsy: A study of 86 outpatients. Archives of Sexual Behavior, 1990, 19, 1-14.	1.9	79
81	A systematic review of the incidence and prevalence of cancer in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 294-304.	3.0	79
82	Intracerebral haemorrhage after carotid endarterectomy. European Journal of Vascular Surgery, 1987, 1, 51-60.	0.9	77
83	Cognitive impairment in newly diagnosed multiple sclerosis patients: A 4-year follow-up study. Journal of the Neurological Sciences, 2006, 245, 77-85.	0.6	75
84	CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 877-884.	3.0	75
85	A genome-wide screen for linkage in Nordic sib-pairs with multiple sclerosis. Genes and Immunity, 2002, 3, 279-285.	4.1	73
86	Association between an interleukinâ€13 promoter polymorphism and atopy. International Journal of Immunogenetics, 2003, 30, 355-359.	1.2	73
87	Clinical course and prognosis of pseudotumor cerebri. A prospective study of 24 patients. Acta Neurologica Scandinavica, 1988, 77, 164-172.	2.1	71
88	Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurology, The, 2010, 9, 672-680.	10.2	70
89	Flunarizine Versus Metoprolol in Migraine Prophylaxis: A Double-Blind, Randomized Parallel Group Study of Efficacy and Tolerability. Headache, 1991, 31, 650-657.	3.9	68
90	Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab. Multiple Sclerosis and Related Disorders, 2016, 10, 169-173.	2.0	68

#	Article	IF	Citations
91	Safety and immunogenicity of a new formulation of interferon Î²-1a (RebifÂ® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Multiple Sclerosis Journal, 2009, 15, 219-228.	3.0	67
92	Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis. Journal of Neuroinflammation, 2012, 9, 215.	7.2	66
93	The efficacy of multidisciplinary rehabilitation in stable multiple sclerosis patients. Multiple Sclerosis Journal, 2006, 12, 235-242.	3.0	65
94	Multiple sclerosis and polymorphisms of innate pattern recognition receptors TLR1-10, NOD1-2, DDX58, and IFIH1. Journal of Neuroimmunology, 2009, 212, 125-131.	2.3	65
95	Safety concerns and risk management of multiple sclerosis therapies. Acta Neurologica Scandinavica, 2017, 136, 168-186.	2.1	65
96	Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-Î² treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Multiple Sclerosis Journal, 2008, 14, 622-630.	3.0	64
97	Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 32-42.	3.0	64
98	Sumatriptan has no clinically relevant effect in the treatment of episodic tensionâ€type headache. European Journal of Neurology, 1996, 3, 23-28.	3.3	63
99	Why does the northâ€“south gradient of incidence of multiple sclerosis seem to have disappeared on the Northern hemisphere?. Journal of the Neurological Sciences, 2011, 311, 58-63.	0.6	63
100	Correlation of Global N-Acetyl Aspartate With Cognitive Impairment in Multiple Sclerosis. Archives of Neurology, 2006, 63, 533.	4.5	61
101	Prevalence of stroke in a district of Copenhagen. Acta Neurologica Scandinavica, 1982, 66, 68-81.	2.1	61
102	Neutralizing antibodies hamper IFNÎ² bioactivity and treatment effect on MRI in patients with MS. Neurology, 2006, 67, 1681-1683.	1.1	60
103	The changing course of multiple sclerosis: rising incidence, change in geographic distribution, disease course, and prognosis. Current Opinion in Neurology, 2019, 32, 320-326.	3.6	60
104	Effect of Natalizumab on Circulating CD4+ T-Cells in Multiple Sclerosis. PLoS ONE, 2012, 7, e47578.	2.5	59
105	MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials, 2019, 20, 263.	1.6	58
106	Resistance to cerebrospinal fluid outflow and intracranial pressure in patients with hydrocephales after subarachnoid haemorrhage. Acta Neurochirurgica, 1987, 88, 79-86.	1.7	57
107	Population-Based Study of Acute Respiratory Infections in Children, Greenland. Emerging Infectious Diseases, 2002, 8, 586-593.	4.3	57
108	Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality. Neurology, 2017, 89, 1668-1675.	1.1	57

#	Article	IF	Citations
109	Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect. Multiple Sclerosis Journal, 2015, 21, 1723-1729.	3.0	56
110	The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. Brain, 2020, 143, 2637-2652.	7.6	56
111	Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E). Multiple Sclerosis Journal, 2002, 8, 295-298.	3.0	55
112	Autoantibodies to myelin basic protein (MBP) in healthy individuals and in patients with multiple sclerosis: a role in regulating cytokine responses to MBP. Immunology, 2009, 128, e451-61.	4.4	55
113	Endocrine Studies in Patients With Pseudotumor Cerebri. Archives of Neurology, 1986, 43, 902.	4.5	54
114	Reproduction and the risk of multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1604-1609.	3.0	54
115	Pulsed immune reconstitution therapy in multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641983691.	3.5	54
116	Assessment of CSF dynamics and venous flow in the superior sagittal sinus by MRI in idiopathic intracranial hypertension: a preliminary study. Neuroradiology, 1994, 36, 350-354.	2.2	52
117	CD4+ memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis. Journal of Neuroimmunology, 2006, 181, 157-164.	2.3	51
118	Persistence of neutralizing antibodies after discontinuation of IFNÎ² therapy in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 247-252.	3.0	51
119	Identification of new sensitive biomarkers for the in vivo response to interferonâ€Î² treatment in multiple sclerosis using DNAâ€array evaluation. European Journal of Neurology, 2009, 16, 1291-1298.	3.3	50
120	Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Multiple Sclerosis Journal, 2011, 17, 1074-1078.	3.0	50
121	High cerebrospinal fluid concentration of glial fibrillary acidic protein (GFAP) in patients with normal pressure hydrocephalus. Journal of the Neurological Sciences, 1985, 70, 269-274.	0.6	49
122	Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis. CNS Drugs, 2020, 34, 269-280.	5.9	49
123	Neutralising antibodies to interferon Î² in multiple sclerosis. Journal of Neurology, 2007, 254, 827-837.	3.6	48
124	Progressive multiple sclerosis, cognitive function, and quality of life. Brain and Behavior, 2018, 8, e00875.	2.2	48
125	Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. Neurological Sciences, 2020, 41, 1647-1650.	1.9	48
126	MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS). Multiple Sclerosis Journal, 2005, 11, 433-440.	3.0	47

#	Article	IF	Citations
127	Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1444-1451.	3.0	47
128	Cerebrospinal fluid vasopressin and increased intracranial pressure. Annals of Neurology, 1984, 15, 435-440.	5.3	46
129	Second occurrence of symptomatic metastatic spinal cord compression and findings of multiple spinal epidural metastases. International Journal of Radiation Oncology Biology Physics, 1995, 33, 595-598.	0.8	46
130	Health-related quality of life in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 386-392.	3.0	46
131	MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. Journal of Neurology, 2013, 260, 1136-1146.	3.6	46
132	Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Multiple Sclerosis Journal, 2019, 25, 819-827.	3.0	46
133	Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsingâ€“remitting multiple sclerosis: the CLARITY Extension study. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628561775336.	3.5	45
134	The T cell regulator gene SH2D2A contributes to the genetic susceptibility of multiple sclerosis. Genes and Immunity, 2001, 2, 263-268.	4.1	44
135	Using measurements of neutralizing antibodies: the challenge of IFNâ€Î² therapy. European Journal of Neurology, 2007, 14, 850-859.	3.3	43
136	Studies of vasopressin in the human cerebrospinal fluid. Acta Neurologica Scandinavica, 1986, 74, 81-102.	2.1	42
137	Long-term prognosis after transient ischemic attacks. Acta Neurologica Scandinavica, 1981, 63, 156-168.	2.1	42
138	Multiple sclerosis impairs regional functional connectivity in the cerebellum. NeuroImage: Clinical, 2014, 4, 130-138.	2.7	42
139	Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. Lancet Neurology, The, 2021, 20, 917-929.	10.2	42
140	Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. Journal of the Neurological Sciences, 2005, 233, 61-65.	0.6	41
141	Persistent disturbances of cognitive functions in patients with pseudotumor cerebri. Acta Neurologica Scandinavica, 1986, 73, 264-268.	2.1	41
142	Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis. PLoS ONE, 2016, 11, e0162752.	2.5	41
143	Minocycline added to subcutaneous interferon Î²â€1a in multiple sclerosis: randomized <scp>RECYCLINE</scp> study. European Journal of Neurology, 2016, 23, 861-870.	3.3	41
144	Disease protection and interleukinâ€10 induction by endogenous interferonâ€Î² in multiple sclerosis?. European Journal of Neurology, 2011, 18, 266-272.	3.3	40

#	Article	IF	Citations
145	Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. Multiple Sclerosis Journal, 2014, 20, 577-587.	3.0	40
146	Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark. Journal of Neurology, 2016, 263, 2484-2493.	3.6	40
147	Impermeability of the bloodâ€cerebrospinal fluid barrier to 1â€deaminoâ€8â€Dâ€arginineâ€vasopressin (DDAVP) in patients with acquired, communicating hydrocephalus. European Journal of Clinical Investigation, 1984, 14, 435-439.	3.4	39
148	Expanded functional coupling of subcortical nuclei with the motor resting-state network in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 559-566.	3.0	39
149	The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review. Multiple Sclerosis Journal, 2015, 21, 332-341.	3.0	39
150	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. Multiple Sclerosis Journal, 2020, 26, 1031-1044.	3.0	39
151	Visual Evoked Potentials in Pseudotumor Cerebri. Archives of Neurology, 1985, 42, 150-153.	4.5	38
152	Are ex vivo neutralising antibodies against IFN-Î² always detrimental to therapeutic efficacy in multiple sclerosis?. Multiple Sclerosis Journal, 2007, 13, 616-621.	3.0	38
153	Immunogenicity and tolerability of an investigational formulation of interferon-Î²1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. Clinical Therapeutics, 2007, 29, 1128-1145.	2.5	38
154	A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod. Multiple Sclerosis Journal, 2017, 23, 234-241.	3.0	38
155	High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. Multiple Sclerosis Journal, 2017, 23, 675-685.	3.0	38
156	Correlations of brain MRI parameters to disability in multiple sclerosis. Acta Neurologica Scandinavica, 2001, 104, 24-30.	2.1	37
157	Therapeutic Considerations for Disease Progression in Multiple Sclerosis. Archives of Neurology, 2005, 62, 1519-30.	4.5	36
158	Comparative effectiveness of teriflunomide and dimethyl fumarate. Neurology, 2019, 92, e1811-e1820.	1.1	36
159	Measuring and evaluating interferon b-induced antibodies in patients with multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 39-46.	3.0	35
160	Gene expression analysis of interferon-Î² treatment in multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 615-621.	3.0	35
161	The Danish Multiple Sclerosis Treatment Register. Clinical Epidemiology, 2016, Volume 8, 549-552.	3.0	35
162	CSFâ€amine metabolites in depression, dementia and in controls. Acta Psychiatrica Scandinavica, 1987, 75, 619-628.	4.5	34

#	Article	IF	Citations
163	FOXP3, CBLBandITCHgene expression and cytotoxic T lymphocyte antigen 4 expression on CD4+CD25high T cells in multiple sclerosis. Clinical and Experimental Immunology, 2012, 170, 149-155.	2.6	34
164	Chronic cerebrospinal venous insufficiency and venous stenoses in multiple sclerosis. Acta Neurologica Scandinavica, 2012, 126, 421-427.	2.1	34
165	Cytokine profiles show heterogeneity of interferon-Î² response in multiple sclerosis patients. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e202.	6.0	34
166	Defining active progressive multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1727-1735.	3.0	34
167	Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. PLoS ONE, 2017, 12, e0170395.	2.5	34
168	Review: Neutralizing antibodies against interferon-beta. Therapeutic Advances in Neurological Disorders, 2008, 1, 125-141.	3.5	33
169	Resting-state connectivity of pre-motor cortex reflects disability in multiple sclerosis. Acta Neurologica Scandinavica, 2013, 128, n/a-n/a.	2.1	33
170	Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. Multiple Sclerosis Journal, 2021, 27, 1543-1555.	3.0	33
171	Long-term prognosis and quality of life after reversible cerebral ischemic attacks. Acta Neurologica Scandinavica, 1989, 79, 204-213.	2.1	32
172	The role of intravenous immunoglobulin in the treatment of multiple sclerosis. Journal of the Neurological Sciences, 2003, 206, 123-130.	0.6	32
173	Vasopressin in the cerebrospinal fluid of patients with normal pressure hydrocephalus and benign intracranial hypertension. European Journal of Endocrinology, 1982, 100, 211-215.	3.7	31
174	Absence of hydrocephalus in spite of impaired cerebrospinal fluid absorption and severe intracranial hypertension. Acta Neurochirurgica, 1987, 86, 93-97.	1.7	31
175	Responsiveness of the Multiple Sclerosis Impairment Scale in comparison with the Expanded Disability Status Scale. Multiple Sclerosis Journal, 2005, 11, 81-84.	3.0	30
176	Low cerebrospinal fluid concentration of brain-specific protein D2 in patients with normal pressure hydrocephalus. Journal of the Neurological Sciences, 1983, 62, 59-65.	0.6	29
177	Linkage analysis of a candidate region in Scandinavian sib pairs with multiple sclerosis reveals linkage to chromosome 17q. Genes and Immunity, 2000, 1, 456-459.	4.1	29
178	Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients. Multiple Sclerosis Journal, 2010, 16, 942-949.	3.0	29
179	Cladribine tablets for relapsingâ€“remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study. Multiple Sclerosis and Related Disorders, 2012, 1, 49-54.	2.0	29
180	Gene expression analysis of relapsingâ€“remitting, primary progressive and secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1841-1848.	3.0	29

#	Article	IF	Citations
181	Immunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey. Multiple Sclerosis Journal, 2006, 12, 253-264.	3.0	28
182	Gender and autoimmune comorbidity in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1244-1251.	3.0	28
183	Association between age at onset of multiple sclerosis and vitamin D levelâ€“related factors. Neurology, 2016, 86, 88-93.	1.1	28
184	Worsening of disability caused by relapses in multiple sclerosis: A different approach. Multiple Sclerosis and Related Disorders, 2019, 32, 1-8.	2.0	28
185	Cerebrospinal fluid bombesin and calcitonin in patients with central nervous system metastases from small-cell lung cancer.. Journal of Clinical Oncology, 1986, 4, 1620-1627.	1.6	27
186	Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 179-187.	3.0	27
187	The window of opportunity for treatment of progressive multiple sclerosis. Current Opinion in Neurology, 2020, 33, 262-270.	3.6	27
188	Severe headache as the only symptom of long-standing shunt dysfunction in hydrocephalic children with normal or slit ventricles revealed by computed tomography. Child's Nervous System, 1985, 1, 49-52.	1.1	26
189	Dynamic Tâ€lymphocyte Chemokine Receptor Expression Induced by Interferonâ€beta Therapy in Multiple Sclerosis. Scandinavian Journal of Immunology, 2006, 64, 155-163.	2.7	26
190	Fitbeat: COVID-19 estimation based on wristband heart rate using a contrastive convolutional auto-encoder. Pattern Recognition, 2022, 123, 108403.	8.1	26
191	Essential tremor treated with propranolol: Lack of correlation between clinical effect and plasma propranolol levels. Annals of Neurology, 1981, 9, 53-57.	5.3	25
192	Do concentrations of neurotransmitters measured in lumbar cerebrospinal fluid reflect the concentrations at brain level?. Acta Neurochirurgica, 1988, 91, 55-59.	1.7	25
193	Multi-slice echo-planar spectroscopic MR imaging provides both global and local metabolite measures in multiple sclerosis. Magnetic Resonance in Medicine, 2005, 53, 750-759.	3.0	25
194	Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferonâ€Î². European Journal of Neurology, 2009, 16, 43-47.	3.3	25
195	Concordance for disease course and age of onset in Scandinavian multiple sclerosis coaffected sib pairs. Multiple Sclerosis Journal, 2004, 10, 5-8.	3.0	24
196	NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk. Neuron, 2016, 92, 333-335.	8.1	24
197	Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1298-1305.	3.0	24
198	Effects of long-term carbamazepine treatment on water metabolism and plasma vasopressin concentration. European Journal of Clinical Pharmacology, 1984, 26, 719-722.	1.9	23

#	Article	IF	Citations
199	Comparison of myelography combined with postmyelographic spinal CT and MRI in suspected metastatic disease of the spinal canal. Journal of Neuro-Oncology, 1992, 13, 231-7.	2.9	23
200	Is the treatment effect of IFN-Î² restored after the disappearance of neutralizing antibodies?. Multiple Sclerosis Journal, 2008, 14, 837-842.	3.0	23
201	The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 601-605.	3.0	23
202	Genetic variants of CC chemokine genes in experimental autoimmune encephalomyelitis, multiple sclerosis and rheumatoid arthritis. Genes and Immunity, 2010, 11, 142-154.	4.1	23
203	Principles of a new treatment algorithm in multiple sclerosis. Expert Review of Neurotherapeutics, 2011, 11, 351-362.	2.8	23
204	Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 926-934.	3.0	23
205	Expert opinion on the use of cladribine tablets in clinical practice. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642093501.	3.5	23
206	Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. Neurology, 2004, 63, S42-9.	1.1	23
207	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. Journal of Neuroimmunology, 2019, 326, 19-27.	2.3	22
208	Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 323-328.	3.0	21
209	Prediction of antibody persistency from antibody titres to natalizumab. Multiple Sclerosis Journal, 2012, 18, 1493-1499.	3.0	21
210	Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 305-313.	3.0	21
211	Prediction of response to interferon therapy in multiple sclerosis. Acta Neurologica Scandinavica, 2014, 130, 268-275.	2.1	21
212	Physical and social environment and the risk of multiple sclerosis. Multiple Sclerosis and Related Disorders, 2014, 3, 600-606.	2.0	21
213	Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine. Multiple Sclerosis Journal, 2016, 22, 944-954.	3.0	21
214	Chronic comorbidity in multiple sclerosis is associated with lower incomes and dissolved intimate relationships. European Journal of Neurology, 2017, 24, 825-834.	3.3	21
215	Aggressive multiple sclerosis (2): Treatment. Multiple Sclerosis Journal, 2020, 26, 1045-1063.	3.0	21
216	Correlates of heterosexual behavior among 23-87 year olds in Denmark and Sweden, 1992-1998. Archives of Sexual Behavior, 2000, 29, 91-106.	1.9	20

#	Article	IF	Citations
217	Intravenous immunoglobulin ameliorates experimental autoimmune encephalomyelitis and reduces neuropathological abnormalities when administered prophylactically. Neurological Research, 2005, 27, 591-597.	1.3	20
218	Radiologic features compared to clinical findings in a prospective study of 153 patients with metastatic spinal cord compression treated by radiotherapy. Acta Neurochirurgica, 1997, 139, 105-111.	1.7	19
219	Fatal neurogenic pulmonary edema in a patient with progressive multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 711-715.	3.0	19
220	No linkage or association of the nitric oxide synthase genes to multiple sclerosis. Journal of Neuroimmunology, 2001, 119, 95-100.	2.3	18
221	IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions. Experimental Brain Research, 2007, 178, 462-469.	1.5	18
222	Prevalence of Mitral Valve Prolapse in Younger Patients with Cerebral Ischaemic Attacks. Acta Medica Scandinavica, 1984, 216, 385-391.	0.0	18
223	Cognitive deficits in multiple sclerosis: correlations with T2 changes in normal appearing brain tissue. Acta Neurologica Scandinavica, 2012, 125, 338-344.	2.1	18
224	Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab. Multiple Sclerosis Journal, 2013, 19, 1226-1229.	3.0	18
225	Endogenous Interferon-Î²-Inducible Gene Expression and Interferon-Î²-Treatment Are Associated with Reduced T Cell Responses to Myelin Basic Protein in Multiple Sclerosis. PLoS ONE, 2015, 10, e0118830.	2.5	18
226	Genetic and environmental determinants of 25-hydroxyvitamin D levels in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1414-1422.	3.0	18
227	Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta. Journal of Immunological Methods, 2016, 430, 1-9.	1.4	18
228	Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy. Journal of Neurology, 2019, 266, 306-315.	3.6	18
229	Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study. Multiple Sclerosis and Related Disorders, 2020, 40, 101956.	2.0	18
230	Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsingâ€“Remitting Multiple Sclerosis Patients? A Narrative Review. Neurology and Therapy, 2020, 9, 55-66.	3.2	18
231	Significantly increased fractions of transformed to total Î±2-macroglobulin concentrations in plasma from patients with multiple sclerosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2004, 1690, 203-207.	3.8	17
232	The relationship between MRI and PET changes and cognitive disturbances in MS. Journal of the Neurological Sciences, 2006, 245, 99-102.	0.6	17
233	Association between DPP6 polymorphism and the risk of progressive multiple sclerosis in Northern and Southern Europeans. Neuroscience Letters, 2012, 530, 155-160.	2.1	17
234	Secondary Progressive and Relapsing Remitting Multiple Sclerosis Leads to Motor-Related Decreased Anatomical Connectivity. PLoS ONE, 2014, 9, e95540.	2.5	17

#	Article	IF	Citations
235	Short-term, high-dose glucocorticoid treatment does not contribute to reduced bone mineral density in patients with multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1557-1565.	3.0	17
236	Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network. Frontiers in Neurology, 2021, 12, 647811.	2.4	17
237	Cerebrospinal fluid vasopressin as a marker of central nervous system metastases from small-cell bronchogenic carcinoma.. Journal of Clinical Oncology, 1985, 3, 48-53.	1.6	16
238	Inverse comorbidity in multiple sclerosis: Findings in a complete nationwide cohort. Multiple Sclerosis and Related Disorders, 2016, 10, 181-186.	2.0	16
239	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis Journal, 2022, 28, 1424-1456.	3.0	16
240	Vasopressin release during electroconvulsive therapy. Psychoneuroendocrinology, 1982, 7, 303-308.	2.7	15
241	Two genome-wide linkage disequilibrium screens in Scandinavian multiple sclerosis patients. Journal of Neuroimmunology, 2003, 143, 101-106.	2.3	15
242	Intravenous Polyclonal Human Immunoglobulins in Multiple Sclerosis. Neurodegenerative Diseases, 2008, 5, 8-15.	1.4	15
243	The incidence and clinical presentation of neurosyphilis in Greater Copenhagen 1974 through 1978. Acta Neurologica Scandinavica, 1981, 63, 237-246.	2.1	15
244	Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis. Journal of the Neurological Sciences, 2011, 311, S29-S34.	0.6	15
245	Correlation between antiâ€interferonâ€Î² binding and neutralizing antibodies in interferonâ€Î²â€treated multiple sclerosis patients. European Journal of Neurology, 2012, 19, 1311-1317.	3.3	15
246	Gender effects on treatment response to interferon-beta in multiple sclerosis. Acta Neurologica Scandinavica, 2014, 130, 374-379.	2.1	15
247	Neurofilament in CSFâ€”A biomarker of disease activity and long-term prognosis in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1112-1113.	3.0	15
248	Early safety and efficacy of fingolimod treatment in Denmark. Acta Neurologica Scandinavica, 2017, 135, 129-133.	2.1	15
249	Clinically stable disease is associated with a lower risk of both income loss and disability pension for patients with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 67-74.	1.9	15
250	Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	15
251	Laquinimod Safety Profile. International Journal of MS Care, 2017, 19, 16-24.	1.0	15
252	Population Pharmacokineticâ€“BÂCell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis. CNS Drugs, 2022, 36, 283-300.	5.9	15

#	Article	IF	Citations
253	Multiple sclerosis: pathophysiology revisited. Lancet Neurology, The, 2005, 4, 9-10.	10.2	14
254	CD26+CD4+T cell counts and attack risk in interferon-treated multiple sclerosis. Multiple Sclerosis Journal, 2005, 11, 641-645.	3.0	14
255	The effect of Î²-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis. Clinical Immunology, 2008, 129, 80-89.	3.2	14
256	The SH2D2A gene and susceptibility to multiple sclerosis. Journal of Neuroimmunology, 2008, 197, 152-158.	2.3	14
257	Neutralizing antibodies against interferon-Î² do not predispose antibodies against natalizumab. Neurology, 2011, 76, 759-760.	1.1	14
258	Endogenous and Recombinant Type I Interferons and Disease Activity in Multiple Sclerosis. PLoS ONE, 2012, 7, e35927.	2.5	14
259	Electroconvulsive therapy: A comparison of seizure duration as monitored with electroencephalograph and electromyograph. Acta Psychiatrica Scandinavica, 1981, 64, 193-198.	4.5	12
260	Bone lesions in early syphilis detected by bone scintigraphy.. Sexually Transmitted Infections, 1984, 60, 265-268.	1.9	11
261	Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 2007, 69, 1552-1553.	1.1	11
262	A Case of Malignant Lymphoma and Myasthenia Gravis. Scandinavian Journal of Haematology, 1983, 31, 155-160.	0.0	11
263	Cerebral metabolism, magnetic resonance spectroscopy and cognitive dysfunction in early multiple sclerosis: an exploratory study. Neurological Research, 2012, 34, 52-58.	1.3	11
264	Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis. Clinical Drug Investigation, 2012, 32, 15-27.	2.2	11
265	Ozanimod: a better or just another S1P receptor modulator?. Lancet Neurology, The, 2016, 15, 345-347.	10.2	11
266	Monoclonal Antibodies for Relapsing Multiple Sclerosis: A Review of Recently Marketed and Late-Stage Agents. CNS Drugs, 2017, 31, 357-371.	5.9	11
267	Predictors of treatment outcome in patients with paediatric onset multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 964-975.	3.0	11
268	Cerebrospinal fluid and plasma vasopressin during short-time induced intracranial hypertension. Acta Neurochirurgica, 1985, 77, 46-51.	1.7	10
269	Tolfenamic acid versus propranolol in the prophylactic treatment of migraine. Acta Neurologica Scandinavica, 1994, 89, 446-450.	2.1	10
270	Educational achievements of children of parents with multiple sclerosis: A nationwide register-based cohort study. Journal of Neurology, 2016, 263, 2229-2237.	3.6	10

#	Article	IF	Citations
271	Prognostic Value of in vitro Measurements of Platelet Aggregability and Fibrinolytic Activity in Patients with Reversible Cerebral Ischemic Attacks. European Neurology, 1983, 22, 437-441.	1.4	9
272	24-hour cerebrospinal fluid levels of vasopressin in hydrocephalic patients. Regulatory Peptides, 1985, 10, 115-126.	1.9	9
273	Ophthalmologic prognosis in Benign Intracranial Hypertension. Acta Ophthalmologica, 1985, 63, 62-64.	1.1	9
274	Alterations in KLRB1 gene expression and a Scandinavian multiple sclerosis association study of the KLRB1 SNP rs4763655. European Journal of Human Genetics, 2011, 19, 1100-1103.	2.8	9
275	CorticalN-acetyl aspartate is a predictor of long-term clinical disability in multiple sclerosis. Neurological Research, 2014, 36, 701-708.	1.3	9
276	The chemokine receptorCCR5 Î”32allele in natalizumab-treated multiple sclerosis. Acta Neurologica Scandinavica, 2014, 129, 27-31.	2.1	9
277	Therapeutic interference with leukocyte recirculation in multiple sclerosis. European Journal of Neurology, 2015, 22, 434-442.	3.3	9
278	Employment, disability pension and income for children with parental multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1148-1156.	3.0	9
279	Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110582.	3.5	9
280	Immunological effects of methylprednisolone pulse treatment in progressive multiple sclerosis. Journal of Neuroimmunology, 2014, 276, 195-201.	2.3	8
281	Recovery from an acute relapse is associated with changes in motor resting-state connectivity in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 912-914.	1.9	8
282	Spinal cord atrophy in anterior-posterior direction reflects impairment in multiple sclerosis. Acta Neurologica Scandinavica, 2017, 136, 330-337.	2.1	8
283	Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 188-197.	3.0	8
284	The effectiveness of natalizumab vs fingolimodâ€“A comparison of international registry studies. Multiple Sclerosis and Related Disorders, 2021, 53, 103012.	2.0	8
285	Antibodies to IFN-beta. Neurology, 2003, 61, S27-8.	1.1	8
286	Oral fumarate for relapsing-remitting multiple sclerosis. Lancet, The, 2008, 372, 1447-1448.	13.7	7
287	Management of patients with neutralizing antibodies against interferonâ€beta: stop IFNâ€beta therapy or wait for the antibodies to go away?. European Journal of Neurology, 2009, 16, 1-2.	3.3	7
288	Effects of fingolimod in relapsing-remitting multiple sclerosis. Lancet Neurology, The, 2014, 13, 526-527.	10.2	7

#	Article	IF	Citations
289	Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 556-562.	1.9	7
290	Age and sex as determinants of treatment decisions in patients with relapsing-remitting MS. Multiple Sclerosis and Related Disorders, 2021, 50, 102813.	2.0	7
291	Intravenous immunoglobulin G therapy: effects of acute and chronic treatment in multiple sclerosis. Multiple Sclerosis Journal, 1996, 1, 349-352.	3.0	6
292	Intravenous Immunoglobulin Treatment in Neurologic Disorders. Archives of Neurology, 1999, 56, 1025.	4.5	6
293	Effects of neutralizing antibodies to interferon beta in multiple sclerosis: a logical paradox. Multiple Sclerosis Journal, 2012, 18, 131-132.	3.0	6
294	Preserved in vivo response to interferon-alpha in multiple sclerosis patients with neutralising antibodies against interferon-beta (REPAIR study). Multiple Sclerosis and Related Disorders, 2013, 2, 141-146.	2.0	6
295	Generic glatiramer acetate â€" a step toward cheaper MS drugs?. Nature Reviews Neurology, 2016, 12, 5-6.	10.1	6
296	Disability in progressive MS is associated with T2 lesion changes. Multiple Sclerosis and Related Disorders, 2018, 20, 73-77.	2.0	6
297	Clinical characteristics and use of disease modifying therapy in the nationwide Danish cohort of paediatric onset multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 37, 101431.	2.0	6
298	Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis. CNS Drugs, 2022, 36, 569-589.	5.9	6
299	Prophylactic Effect of Flunarizine versus Metoprolol in Migraine. Cephalalgia, 1989, 9, 355-356.	3.9	5
300	Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis. Expert Review of Neurotherapeutics, 2013, 13, 1309-1317.	2.8	5
301	Relapses add to permanent disability in relapsing multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2021, 53, 103029.	2.0	5
302	Linkage analysis suggests a region of importance for multiple sclerosis in 3p14â€“13. Genes and Immunity, 2001, 2, 451-454.	4.1	4
303	Reporting clinical trials: full access to all the data. European Journal of Neurology, 2002, 9, 123-124.	3.3	4
304	The gap between effect of drugs and effectiveness of treatments. Journal of the Neurological Sciences, 2007, 259, 128-132.	0.6	4
305	REGARD: what can we learn from randomised, open-label, head-to-head studies?. Lancet Neurology, The, 2008, 7, 864-866.	10.2	4
306	Haematopoietic stem cell transplants should be a second-line therapy for highly active MS â€" NO. Multiple Sclerosis Journal, 2016, 22, 1260-1263.	3.0	4

#	Article	IF	Citations
307	Treatment of Hookworm Anemia. Scandinavian Journal of Infectious Diseases, 1971, 3, 65-69.	1.5	3
308	Neutralising antibodies against interferon beta in multiple sclerosis. Lancet, The, 2004, 363, 168-169.	13.7	3
309	Cladribine in the treatment of multiple sclerosis. Clinical Investigation, 2011, 1, 317-326.	0.0	3
310	039â€¦Rates of lymphopenia in years 1â€“4 in patients with relapsing multiple sclerosis treated annually with cladribine tablets. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A16.2-A16.	1.9	3
311	Averting multiple sclerosis long-term societal and healthcare costs: The Value of Treatment (VoT) project. Multiple Sclerosis and Related Disorders, 2021, 54, 103107.	2.0	3
312	Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. Journal of International Medical Research, 2008, 36, 204-8; author reply 208-10.	1.0	3
313	Carotid artery disease and low cerebral perfusion pressure: symptomatology, operative risk and outcome. Neurological Research, 1990, 12, 35-40.	1.3	2
314	Central motor conduction as a measure of disease progression in early multiple sclerosis. European Journal of Neurology, 1995, 1, 233-241.	3.3	2
315	A new millennium? Perhaps. A new European Journal of Neurology? Certainly!. European Journal of Neurology, 2000, 7, 1-1.	3.3	2
316	A prospective PET study of patients with glioblastoma multiforme. Acta Neurologica Scandinavica, 2006, 113, 412-418.	2.1	2
317	Neutralising antibodies to interferon-Î²â€“measurement, clinical relevance, and management. Journal of Neurology, 2006, 253, vi16-vi22.	3.6	2
318	Can we spot the IFNÂ nonresponders?. Neurology, 2008, 71, 1936-1937.	1.1	2
319	Plasma Vasopressin, Cortisol, and Growth Hormone Concentrations in Relation to Surgery in the Suprasellar Region. Acta Medica Scandinavica, 1984, 216, 31-39.	0.0	2
320	Cardiac Disease in Patients with Reversible Cerebral Ischemic Events. Acta Medica Scandinavica, 1985, 217, 417-421.	0.0	2
321	Comparison of clinical neurological function and CT response during chemotherapy for initial brain metastases from small cell lung cancer. Acta Neurologica Scandinavica, 2009, 89, 372-377.	2.1	2
322	Deaths and disability from natalizumab are no longer tolerable: No â€“ (they can be avoided). Multiple Sclerosis Journal, 2012, 18, 1070-1072.	3.0	2
323	Elektromyografisk monitorering ved narko-curare-elektrostimulation. Nordic Journal of Psychiatry, 1979, 33, 9-14.	0.1	1
324	The Effect on MRI of Gammaglobulin Treatment in Relapsing Multiple Sclerosis. Multiple Sclerosis Journal, 2000, 6, S14-S17.	3.0	1

#	Article	IF	Citations
325	Early-Stage Multiple Sclerosis. Drugs, 2004, 64, 2021-2029.	10.9	1
326	How effective is natalizumab as secondâ€line treatment for multiple sclerosis in daily clinical praxis?. European Journal of Neurology, 2009, 16, 287-288.	3.3	1
327	Gene expression in smoking and non-smoking patients with multiple sclerosis. Journal of Neuroimmunology, 2014, 275, 49.	2.3	1
328	Effectiveness of glatiramer acetate in neutralizing antibody-positive patients previously treated with interferon-Î². Multiple Sclerosis and Related Disorders, 2020, 39, 101894.	2.0	1
329	Transcriptome and Function of Novel Immunosuppressive Autoreactive Invariant Natural Killer T Cells That Are Absent in Progressive Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e1065.	6.0	1
330	A follow-up study of Nordic multiple sclerosis candidate gene regions. Multiple Sclerosis Journal, 2007, 13, 584-589.	3.0	0
331	Resource allocation to brain research in Europe. European Journal of Neurology, 2007, 14, 597-597.	3.3	0
332	Editorial. Journal of Neurology, 2008, 255, 1-2.	3.6	0
333	447: Remyelination is extensive in a subset of multiple sclerosis patients. Journal of Clinical Neuroscience, 2008, 15, 358.	1.5	0
334	Neutralizing antibodies directed against biologic agents to treat multiple sclerosis. , 0, , 287-299.		0
335	Intravenous immunoglobulin to treat multiple sclerosis. , 0, , 444-453.		0
336	The SH2D2A Gene -Contributions to Our Future Understanding of Multiple Sclerosis. European Neurological Review, 2009, 4, 68.	0.5	0
337	Multiple Sclerosis Management â€“ A Changing Landscape 2013. European Neurological Review, 2013, 8, 105.	0.5	0